Article

Efficacy of late-onset antiviral treatment in immune-compromised hosts with persistent SARS-CoV-2 infection

2024-05-23

Abstract excerpt

The immunocompromised are at high risk of prolonged SARS-CoV-2 infection and progression to severe COVID-19. However, efficacy of late-onset direct-acting antiviral (DAA) therapy with therapeutics in clinical use and experimental drugs to mitigate persistent viral replication is unclear. In this study, we employed an immunocompromised mouse model, which supports prolonged replication of SARS-CoV-2 to explore late-...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 7a8e3e33-8e54-5813-8d93-dc08a7b45620
DOI: 10.1101/2024.05.23.595478

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Efficacy of late-onset antiviral treatment in immune-compromised hosts with persistent SARS-CoV-2 infectionDOI 10.1101/2024.05.23.595478Read

The effect of molnupiravir and nirmatrelvir on SARS-CoV-2 genome diversity in severe models of COVID-19Semantic proximity Read

Combination therapy with nirmatrelvir and molnupiravir improves the survival of SARS-CoV-2 infected miceSemantic proximity Read

A Mouse Model of SARS-CoV-2-Driven Acute Maladaptive Responses and Chronic Systemic DiseasesSemantic proximity Read

Early combination of sotrovimab with nirmatrelvir/ritonavir or remdesivir is associated with low rate of persisting SARS CoV-2 infection in immunocompromised outpatients with mild-to-moderate COVID-19: a prospective single center studySemantic proximity Read

A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasuresSemantic proximity Read

A stem-loop RNA RIG-I agonist confers prophylactic and therapeutic protection against acute and chronic SARS-CoV-2 infection in miceSemantic proximity Read

Clinical phenotype and outcome of persistent SARS-CoV-2 replication in immunocompromised hosts: a retrospective observational study in the Omicron era.Semantic proximity Read

Combination therapy with oral antiviral and anti-inflammatory drugs improves the efficacy of delayed treatment in severe COVID-19Semantic proximity Read

Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use caseSemantic proximity Read

Subcutaneous REGEN-COV Antibody Combination for Covid-19 PreventionSemantic proximity Read

Type I Interferon Limits Viral Dissemination-Driven Clinical Heterogeneity in a Native Murine Betacoronavirus Model of COVID-19Semantic proximity Read

Comprehensive analysis of disease pathology in immunocompetent and immunocompromised hamster models of SARS-CoV-2 infectionSemantic proximity Read